Tag: beigene

June 9, 2021

5 Small Biotech ETFs

Want to invest in small biotech ETFs? INN profiles five examples that life science investors may want to look into.
January 15, 2019

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib

BeiGene (NASDAQ:BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the...
December 20, 2018

5 Top Biotech and Pharma Stocks on the TSX Year-to-Date

Which biotech and pharma stocks on the TSX have performed the best in 2018? Here's a look at the top...
November 27, 2018

Zymeworks and BeiGene Announce License and Collaboration Agreement

Zymeworks (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company...
October 24, 2018

BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib

BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of...
October 10, 2018

BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of...
August 31, 2018

BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China

BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...